Dynamic Octreotide scintigraphy in neuroendocrine tumours

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmacology

Background:

• Neuroendocrine tumors (NETs) are a diverse group of malignancies.
• Octreotide scintigraphy is a key diagnostic tool for NETs.
• Optimizing imaging protocols enhances diagnostic accuracy.

Purpose of the Study:

• To determine the optimal time for scintigraphy after radio-labeled somatostatin analogue (Octreotide) injection.
• To evaluate the diagnostic utility of Single-Photon Emission Computed Tomography (SPECT) in conjunction with Octreotide imaging.

Main Methods:

• 22 patients with NETs underwent imaging after injection of 110 MBq In-DTPA Octreotide.
• Whole body scans and SPECT were performed at 0.5, 5, 24, and 48 hours post-injection.
• A total of 98 scintigrams were analyzed for pathological uptake.

Main Results:

• Pathological uptake indicative of NETs was identified in 19 out of 22 patients.
• Early scintigrams (0.5 and 5 hours) were most valuable in 3 cases; late scintigrams (24 and 48 hours) were best in 4 cases.
• SPECT imaging proved valuable in 13 out of 21 evaluated cases.

Conclusions:

• Both early and late Octreotide scintigraphy are crucial for accurate interpretation.
• SPECT imaging adds significant diagnostic value to Octreotide scintigraphy for NETs.
• A comprehensive imaging approach including early, late scans, and SPECT is recommended for optimal NET diagnosis.